BioSpace News Archive

MYND Life Sciences Inc. is pleased to announce that CEO, Dr. Lyle Oberg , will be presenting at the Psychedelics in Psychiatry and Beyond conference.

Salarius Pharmaceuticals, Inc. today announced the initiation of a clinical trial to investigate seclidemstat, a novel lysine specific demethylase 1 (LSD1) inhibitor, as a potential treatment for hematologic cancers.

Otonomy, Inc. today announced the initiation of an expansion study for the Phase 1/2 clinical trial of OTO-413 in patients with speech-in-noise hearing difficulty.

NRx Pharmaceuticals today announced positive data from its ZYESAMI™ (Aviptadil) Expanded Access Protocol (EAP).

Organicell Announces Positive Results of Their Expanded Access Trial for the Treatment of Mild to Moderate COVID-19 Using Zofin TM.

Sage Therapeutics today announced it will host a live webcast this morning, June 15, 2021 at 8:00 a.m. ET to review topline results from the Phase 3 WATERFALL Study evaluating zuranolone for major depressive disorder.

Scipher Medicine, a precision immunology company matching patients with the most effective therapy, announced that in an independent validation study, PrismRA accurately predicted which patients with rheumatoid arthritis would not achieve EULAR good response criteria at six months of treatment using either adalimumab or etanercept.

Longeveron Inc., a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced that Geoff Green, Chief Executive Officer of Longeveron, will present virtually at the Investor Forum at the World Stem Cell Summit on Thursday, June 17th at 9:45 AM EDT.

Codiak BioSciences, Inc. today announced the promotion of Sriram Sathyanarayanan, Ph.D.

Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced that the European Patent Office has issued European patent No. 3,258,943 covering AllocetraTM, the Company’s immunotherapy product candidate.